Our top pick for
GenMark Diagnostics, Inc is a medical devices business based in the US. GenMark Diagnostics shares (GNMK) are listed on the NASDAQ and all prices are listed in US Dollars. GenMark Diagnostics employs 437 staff and has a trailing 12-month revenue of around USD$126.9 million.
|52-week range||USD$3.36 - USD$20.88|
|50-day moving average||USD$12.9311|
|200-day moving average||USD$12.9053|
|Wall St. target price||USD$20.6|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.85|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing GenMark Diagnostics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GenMark Diagnostics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GenMark Diagnostics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.15. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GenMark Diagnostics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$126.9 million|
|Gross profit TTM||USD$28.6 million|
|Return on assets TTM||-10.28%|
|Return on equity TTM||-64.13%|
|Market capitalisation||USD$804.5 million|
TTM: trailing 12 months
There are currently 7.0 million GenMark Diagnostics shares held short by investors – that's known as GenMark Diagnostics's "short interest". This figure is 4% down from 7.3 million last month.
There are a few different ways that this level of interest in shorting GenMark Diagnostics shares can be evaluated.
GenMark Diagnostics's "short interest ratio" (SIR) is the quantity of GenMark Diagnostics shares currently shorted divided by the average quantity of GenMark Diagnostics shares traded daily (recently around 960950.82191781). GenMark Diagnostics's SIR currently stands at 7.3. In other words for every 100,000 GenMark Diagnostics shares traded daily on the market, roughly 7300 shares are currently held short.
However GenMark Diagnostics's short interest can also be evaluated against the total number of GenMark Diagnostics shares, or, against the total number of tradable GenMark Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GenMark Diagnostics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 GenMark Diagnostics shares in existence, roughly 100 shares are currently held short) or 0.1137% of the tradable shares (for every 100,000 tradable GenMark Diagnostics shares, roughly 114 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against GenMark Diagnostics.
Find out more about how you can short GenMark Diagnostics stock.
We're not expecting GenMark Diagnostics to pay a dividend over the next 12 months.
Over the last 12 months, GenMark Diagnostics's shares have ranged in value from as little as $3.36 up to $20.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GenMark Diagnostics's is 2.9062. This would suggest that GenMark Diagnostics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.